Pharma giant Bayer has accepted nine healthcare providers for its Digital Health Partnership Program G4A from more than a hundred applicants across nearly 40 countries. In 2021, the company’s focus was on startups in areas of mental health, cardiometabolic and renal diseases, radiology, and women’s health in Europe.

Bayer has selected four early-stage startups for its G4A Growth Track: 1) Cardiokol, a senior-focused heart disease monitoring solution using voice-based biomarkers, 2) Acorai, a non-invasive heart failure monitoring application, 3) Pollie, a chronic conditions management program for women with polycystic ovarian syndrome, and 4) RCube Health, a mental health app for managing stress and anxiety. Each startup will receive EUR 100,000 (USD 113,287) for market uptake as well as Bayer’s mentoring and external industry coaching support.

In addition, Bayer has selected five companies for its G4A Advanced Track, a funding program for mid-sized companies; they are: 1) Liva Healthcare, a personalized chronic care management platform, 2) Cordio Medical, a voice-based ​​solution for monitoring congestive heart failure, 3) Nines, a healthcare radiology provider, 4) Woebot Health, a psychotherapy chatbot for mental disorders, and 5) Zed Technologies, a medical image sharing platform.

Bayer provides pharmaceutical products such as prescription drugs, specialty therapeutics, and radiology as well as a wide range of consumer offerings including nutritional, dermatology, and digestive health products.